Almanac A1C

Akkermansia muciniphila – Mucus Guardian Turned Metabolic Superhero

Posted

by

dr. Karunia Valeriani Japar

Table of Contents
Keywords: , , , , ,

From Commensal to Next-Generation Probiotic

Akkermansia muciniphila has rapidly moved from taxonomic curiosity to focal point of microbiome-based therapeutics since its first isolation in 2004 as an anaerobic, Gram-negative, mucin-degrading bacterium within the phylum Verrucomicrobia from human fecal samples. Early ecological surveys demonstrated that this species preferentially colonizes the intestinal mucus layer, establishes during the first year of life, and can constitute approximately 1-3% of the gut microbiota in healthy adults, supporting its status as a core commensal of the human intestinal ecosystem. As a mucin specialist, A.muciniphila contributes to continuous turnover of the mucus barrier and generates short-chain fatty acids and other metabolites that can be utilized by neighbouring microbes and host tissues, linking its niche activity to barrier integrity and metabolic signalling.

Over the past decade, converging metagenomic and experimental data have revealed a consistent inverse association between A. muciniphila abundance and obesity, insulin resistance , type 2 diabetes, and inflammatory bowel disease, suggesting that loss of this commensal marks or contributes to a transition toward metabolic and immune dysregulation. In mouse models of diet-induced obesity and diabetes, reductions in A.muciniphila recede the onset of adipose inflammation, weight gain, and glucose intolerance, whereas restoration of its levels ameliorates adiposity, hepatic steatosis, low-grade inflammation, and insulin resistance, reinforcing a putative causal role in maintaining metabolic homeostasis. Human observational studies further report that individuals with higher baseline A.muciniphila exhibit healthier metabolic profiles and greater improvement after calorie restriction or bariatric surgery, while early interventional trials with pasteurized A.muciniphila demonstrated improvements in insulin sensitivity, plasma lipids, and inflammatory markers without safety concerns.

These findings have catalyzed the positioning of A.muciniphila as a leading “next-generation probiotic,” distinct from traditional lactic acid bacteria by virtue of its mucus-adapted ecology, host–barrier interface, and multi-system effects that span metabolic, immune, and possibly aging-related pathways. Beyond whole-cell supplementation, attention is now turning to A.muciniphila -derived outer membrane proteins, secreted factors, and extracellular vesicles, which in preclinical models can reproduce or even surpass the benefits of live cells on gut permeability, inflammation, and glucose metabolism, opening a translational avenue for defined postbiotic therapeutics. As metabolic disease and aging-related multimorbidity continue to rise globally, A.muciniphila exemplifies how a single mucin-degrading commensal can be re-envisioned as a biomarker, mechanistic node, and therapeutic candidate at the intersection of gut barrier health, immune balance, and metabolic resilience.

Ecology, Physiology, and Mucin-Degrading Niche

Akkermansia muciniphila is a Gram-negative,** strictly anaerobic bacterium that has evolved to occupy the intestinal mucus layer as its primary ecological niche, where it resides in close proximity to the epithelium and the host immune system. Taxonomically placed within the phylum Verrucomicrobia, A.muciniphila is one of the few gut microbes specialized to use host-derived mucin as a predominant or sole source of carbon and nitrogen, enabling persistence even under conditions of low dietary fiber intake. Quantitative surveys indicate that A.muciniphila colonizes the human gut early in life, can be detected from the first months of infancy, and is present in approximately 50–75% of individuals across age groups, typically accounting for around 1–3% of total bacterial cells in adult feces. Interestingly, its colonization rates are often higher in healthy older or long-lived adults, suggesting that stable A.muciniphila carriage may be a hallmark of resilient gut ecosystems over the lifespan [1,2,3,4,5,6,7].

Within the mucus layer, A.muciniphila expresses a rich repertoire of glycosyl hydrolases and sulfatases that cleave mucin O-glycans, releasing oligosaccharides and monosaccharides which are subsequently fermented into short-chain fatty acids (SCFAs), predominantly acetate and propionate, as well as intermediates such as 1,2-propanediol. These end-products serve not only as energy substrates for the bacterium itself but also fuel neighbouring butyrate-producing taxa, including members of the Clostridiales, through classic cross-feeding networks at the mucosal interface. In co-culture and community-level studies, mucin degradation by A.muciniphila increases the availability of acetate and simple sugars, which are then converted to butyrate by partner microbes, amplifying the local pool of SCFAs that support epithelial energy metabolism, reinforce tight junctions, and modulate immune tolerance. Through this trophic web, A.muciniphila functions as a keystone mucin degrader that couples host-derived mucus turnover to microbial SCFA production, thereby influencing gut barrier thickness, luminal redox conditions, and systemic energy balance [6,7,8,9,10,11].

Akkermansia, Gut Barrier Integrity, and Immune Modulation

The influence of Akkermansia muciniphila on gut barrier integrity and mucosal immunity extends well beyond simple mucin consumption, involving a sophisticated interplay between bacterial effector molecules, epithelial repair pathways, and innate and adaptive immune cell networks. The bacterium’s outer membrane protein Amuc_1100 has emerged as a critical mediator of barrier protection, acting via Toll-like receptor 2 (TLR2) signalling to upregulate tight junction proteins including occludin, zonula occludens-1 (ZO-1), and claudin family members in both cultured intestinal epithelial cells and murine models of high-fat diet and colitis. Mechanistically, Amuc_1100 activates cyclic AMP-responsive element-binding protein H (CREBH) in epithelial cells, which in turn suppresses endoplasmic reticulum stress, promotes expression of microRNA-143/145, and stimulates insulin-like growth factor signaling to accelerate intestinal stem cell proliferation and wound repair. Similarly, extracellular vesicles derived from A.muciniphila (AmEVs) deliver bioactive cargo that enhances tight junction integrity via AMP-activated protein kinase (AMPK) phosphorylation, restores trans-epithelial electrical resistance in inflamed Caco-2 monolayers, and reduces paracellular permeability under lipopolysaccharide challenge or high-fat feeding. Another secreted enzyme, Amuc_2109, reinforces these effects by reducing NLRP3 inflammasome assembly and pro-inflammatory cytokine release in dextran sulfate sodium (DSS)-induced colitis models, while simultaneously preserving goblet cell numbers and mucin layer thickness [5,12,13,14,15,16].

Figure 1. A.munciphila and its membrane protein Amuc_1100 enhances intestinal CREBH expression which in turn ameliorates colonic ER stress and inflammation induced  by DSS and promotes intestinal barrier integrity by upregulating expression of protective gut tight junctions (CLDN5 and CLDN8) but inhibiting the leaky gut mediator, CLDN2 [12].

Beyond epithelial barrier reinforcement, A.muciniphila exerts potent immunomodulatory effects that shift local and systemic immune tone toward tolerance and tissue repair. In DSS colitis, oral administration of live A.muciniphila increases goblet cell hyperplasia, mucin gene expression, and the population of M2 anti-inflammatory macrophages in colonic lamina propria, while decreasing infiltration of CD8⁺ cytotoxic T lymphocytes and reducing tissue levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and chemokine ligand 1 (CXCL1). Interestingly, this protective effect is dependent on activation, not inhibition of the NLRP3 inflammasome; NLRP3-deficient mice lose the therapeutic benefit of A.muciniphila in colitis, highlighting a context in which controlled inflammasome signalling supports mucosal homeostasis and repair rather than driving pathology. In macrophage models, A.muciniphila treatment induces a phenotypic switch from pro-inflammatory M1 (CD80⁺, TNF-α⁺, IL-6⁺) to anti-inflammatory M2 (CD206⁺, IL-10⁺, TGF-β⁺) polarization, an effect observed both as pretreatment prophylaxis and post-exposure intervention. At the level of adaptive immunity, , A.muciniphila supplementation in obese mice and in type 1 diabetes models increases the frequency of FoxP3⁺ regulatory T cells (Tregs) in visceral adipose tissue, mesenteric lymph nodes, pancreatic lymph nodes, and pancreatic islets, while concomitantly reducing IL-17-producing Th17 cells and CD4⁺RORγT⁺ pro-inflammatory populations [5,17,18,19,20,21].

However, the effects of A.muciniphila re highly context-dependent, and under certain conditions of severe dysbiosis or active pathogen infection, colonization by, A.muciniphila an paradoxically worsen inflammation. Early gnotobiotic studies demonstrated that mono-association or colonization with A.muciniphila during Salmonella enterica serovar Typhimurium infection exacerbated cecal inflammation, reduced goblet cell numbers, and increased expression of pro-inflammatory cytokines, likely due to excessive mucin degradation in the absence of a protective commensal consortium. More recent studies have challenged this view, showing that the presence of A.muciniphila within a more complex microbiota context can reduce Salmonella colonization, inhibit epithelial adhesion of the pathogen, and ameliorate colitis severity through competitive exclusion and barrier-protective mechanisms. Similarly, in IL-10-deficient mice that spontaneously develop colitis, A.muciniphila colonization had neutral effects, neither improving nor worsening disease, underscoring the importance of host genetic background and baseline immune competence in determining therapeutic outcome. These divergent findings reinforce the concept that A.muciniphila is not universally beneficial but rather operates as a conditionally beneficial commensal whose net effect depends on microbiota complexity, host immune status, baseline barrier integrity, and the presence or absence of concurrent inflammatory or infectious challenges [5,22,23.24.25].

The inverse association between Akkermansia muciniphila abundance and metabolic syndrome is supported by robust preclinical evidence demonstrating that oral supplementation with this bacterium substantially reduces weight gain, adiposity, hepatic steatosis, and systemic inflammation in diet-induced obesity models. In high-fat diet (HFD) fed mice, A.muciniphila administration at doses of 10⁸–10⁹ colony-forming units per day reduces body weight gain by 30–45%, decreases epididymal white adipose tissue mass, and prevents progression of insulin resistance and glucose intolerance without changes in food intake. Importantly, the decline in A.muciniphila abundance precedes the onset of metabolic dysfunction; in HFD-fed mice, significant reductions in A.muciniphila are detectable as early as three weeks, before substantial weight gain, adipose inflammation, or peripheral insulin resistance emerge, suggesting a causal rather than merely correlative role in metabolic deterioration. In the liver, A.muciniphila  supplementation markedly ameliorates hepatic steatosis by reducing triglyceride accumulation, lipogenic enzyme expression (DGAT2, FASN), and markers of hepatocellular injury including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), while concurrently increasing genes involved in fatty acid oxidation (CPT1A, ACOX1) and peroxisome proliferator-activated receptor-α (PPARα) signalling. These metabolic improvements are mirrored by enhanced insulin sensitivity, reduced fasting glucose, lower circulating triglycerides and leptin, and improved glucose and insulin tolerance test performance, collectively indicating restoration of whole-body glucose and lipid homeostasis [5,26,27,28,29,30,31].

At the mechanistic level, A.muciniphila  orchestrates metabolic protection through multiple integrated pathways. First, by producing short-chain fatty acids particularly acetate and propionate, A.muciniphila  provides substrates that are taken up by colonocytes and hepatocytes, where acetate is metabolized to adenosine monophosphate (AMP), activating the hepatic AMPK/SIRT1/PGC-1α axis, which in turn suppresses lipogenesis, enhances fatty acid β-oxidation, and protects against lipid peroxidation and ferroptosis in metabolic-associated fatty liver disease. AMPK activation also phosphorylates and reinforces tight junction proteins, lowering intestinal permeability and reducing the translocation of bacterial lipopolysaccharide (LPS) into the portal circulation, a phenomenon termed “metabolic endotoxemia” that drives chronic low-grade inflammation in obesity. Second, A.muciniphila  secretes bioactive proteins, most notably an 84 kDa protein designated P9, which binds to intercellular adhesion molecule-2 (ICAM-2) on enteroendocrine L cells and stimulates secretion of glucagon-like peptide-1 (GLP-1), a hormone that enhances insulin secretion, suppresses appetite, slows gastric emptying, and promotes thermogenesis in brown adipose tissue. Concurrently, P9 and other A.muciniphila  components induce uncoupling protein 1 (UCP1) expression in brown adipose tissue and promote browning of white adipose depots, increasing whole-body energy expenditure and reducing fat mass accumulation independent of caloric intake [31,32,33,34,35,36,37,38].

Third, A.muciniphila reshapes adipose tissue immune tone by shifting macrophage polarization from pro-inflammatory M1 (TNF-α⁺, IL-6⁺, CD11c⁺) to anti-inflammatory M2 (CD206⁺, IL-10⁺, arginase-1⁺) phenotypes, reducing local chemokine expression (CCL2, CCL3, CCL7), and expanding the population of FoxP3⁺ regulatory T cells within visceral adipose tissue, mesenteric lymph nodes, and pancreatic islets. This immunometabolic reprogramming attenuates adipose tissue inflammation, preserves adipocyte insulin signalling, and prevents ectopic lipid deposition in liver and muscle. Fourth A.muciniphila  modulates the intestinal endocannabinoid system by increasing levels of 2-oleoylglycerol (2-OG), 2-arachidonoylglycerol (2-AG), and 2-palmitoylglycerol (2-PG), bioactive lipid mediators that activate cannabinoid receptor 2 (CB2) and peroxisome proliferator-activated receptors (PPARα, PPARγ), promoting barrier integrity, suppressing hepatic lipogenesis, and improving systemic insulin sensitivity, a mechanism termed the “metabolic barrier” wherein gut permeability, microbiota composition, and endocannabinoid tone are integrated to govern energy balance and inflammatory status. Together, these pleiotropic mechanisms position A.muciniphila  as a central orchestrator linking mucus-layer ecology, SCFA metabolism, incretin secretion, thermogenesis, immune tolerance, and barrier function to whole-body metabolic resilience [5,28,29,31,39,40,41,42,43].

Diabetes Spectrum: From Insulin Resistance to Type 1 Diabetes

The relationship between Akkermansia muciniphila and diabetes spans a continuum from insulin resistance through overt type 2 diabetes (T2D) to autoimmune type 1 diabetes (T1D), with converging evidence that loss of this commensal marks metabolic and immunological vulnerability whereas its restoration confers glycemic and immunomodulatory protection. In the context of type 2 diabetes, human metagenomic studies have consistently documented reduced A.muciniphila  abundance in patients with prediabetes, newly diagnosed T2D, and most strikingly in individuals with refractory T2D (RT2D) who fail to achieve glycemic control despite standard oral glucose-lowering drugs and insulin therapy. A study comparing 79 T2D patients stratified by hemoglobin A1c (HbA1c) found that those with RT2D (HbA1c ≥8%) harbored significantly A.muciniphila abundance than those achieving optimal control (HbA1c <7%), and A.muciniphila  levels were inversely correlated with both HbA1c and fasting glucose, suggesting that this species reflects and may causally influence the capacity for glucose homeostasis. Interestingly, even among metformin-treated patients, A.muciniphila  depletion persisted in refractory cases, indicating that baseline microbiota status may modulate therapeutic responsiveness [44,45,46,47,48].

Preclinical models corroborate and extend these associations by demonstrating causal effects of A.muciniphila  on glucose and lipid metabolism. In streptozotocin (STZ)-induced diabetic rats, administration of viable or pasteurized A.muciniphila  ameliorates hyperglycemia, reduces HbA1c, improves insulin secretion, enhances glucose tolerance, and attenuates glucolipotoxicity, the combined cytotoxic effects of chronically elevated glucose and free fatty acids on pancreatic β-cells, hepatocytes, and peripheral tissues. Mechanistically, A.muciniphila  reduces oxidative stress markers (malondialdehyde, reactive oxygen species), lowers plasma lipopolysaccharide (LPS) and pro-inflammatory cytokines (TNF-α, IL-6), restores hepatic glycogen content, and normalizes lipid profiles by suppressing hepatic steatosis and triglyceride accumulation. These metabolic improvements are mediated by increased GLP-1 secretion, enhanced intestinal tight junction expression (occludin, ZO-1), reduced metabolic endotoxemia, and activation of hepatic AMPK and fibroblast growth factor 15/19 (FGF15/19) pathways, which collectively improve insulin sensitivity, reduce ectopic lipid deposition, and restore glucose-stimulated insulin secretion from residual β-cells. Notably, in a clinical trial involving T2D patients, a multi-strain probiotic formulation containing A.muciniphila  significantly decreased postprandial glucose and HbA1c, validating preclinical findings in human intervention settings [5,47,48,49,50,51].

In the autoimmune type 1 diabetes setting, the protective role of A.muciniphila  operates through fundamentally different but complementary immunomodulatory mechanisms centered on tolerance induction and regulatory cell expansion. In non-obese diabetic (NOD) mice, the classical spontaneous model of autoimmune diabetes—colonies with higher baseline A.muciniphila  abundance exhibit markedly lower incidence of overt diabetes, and oral supplementation with A.muciniphila  delays disease onset, reduces insulitis severity, and preserves pancreatic β-cell mass. Remarkably, early-life colonization (prior to weaning) with A.muciniphila  exerts stronger protective effects than post-weaning administration, establishing a critical developmental window during which microbial exposure shapes adaptive immune system maturation and T1D susceptibility. Similarly, in STZ-induced T1D models A.muciniphila treatment reduces hyperglycemia incidence, lowers blood glucose levels, and attenuates pancreatic islet destruction independently of shifts in overall gut microbiota composition, indicating a direct microbe-host immune interaction rather than secondary effects mediated by community remodelling [5,51,52].

The immunological basis of A.muciniphila -mediated T1D protection centers on the induction of tolerogenic type-2 conventional dendritic cells (cDC2, characterized as SIRP-α⁺CD11b⁺CD103⁺) and the expansion of FoxP3⁺ regulatory T cells in pancreatic lymph nodes, mesenteric lymph nodes, and pancreatic islets. In vitro, bone marrow-derived dendritic cells differentiated in the presence of A.muciniphila  acquire a tolerogenic phenotype characterized by increased IL-10 and TGF-β secretion, reduced expression of co-stimulatory molecules, and enhanced capacity to induce peripheral Tregs from naïve CD4⁺ T cells. In vivo, A.muciniphila  supplementation increases Treg frequency and absolute numbers in pancreatic tissues while concomitantly reducing pathogenic CD4⁺RORγT⁺ Th17 cells and IgA⁺ B cells in pancreatic lymph nodes, shifting the local immune balance toward tolerance and away from autoimmune destruction. Critically, the protective effect is entirely abrogated in Foxp3-DTR mice depleted of Tregs, confirming that CD4⁺Foxp3⁺ regulatory T cells are mechanistically necessary for A.muciniphila -induced T1D protection. Additional mechanisms include restoration of gut barrier integrity, reduction in bacterial translocation, normalization of gut microbiota diversity, and suppression of systemic inflammation, collectively attenuating the chronic immune activation that drives β-cell autoimmunity. Together, these findings establish A.muciniphila  as a microbiota-based therapeutic candidate spanning the diabetes spectrum, from enhancing insulin sensitivity and reducing glucolipotoxicity in metabolic diabetes to inducing immune tolerance and preserving β-cell mass in autoimmune diabetes [5,52,53,54].

Beyond Metabolism: Inflammation, Infection, Cancer, and Aging

While Akkermansia muciniphila gained initial prominence through its metabolic effects, accumulating evidence now positions this bacterium as a pleiotropic regulator of systemic immunity, oxidative resilience, and tissue homeostasis across diverse pathophysiological contexts that extend well beyond metabolic syndrome and diabetes. In cancer immunotherapy,  A.muciniphila  has emerged as one of the strongest gut microbiota-based predictors of clinical response to immune checkpoint inhibitors (ICIs), particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in epithelial tumors, melanoma, and non-small cell lung cancer (NSCLC). Seminal studies demonstrated that patients harbouring higher baseline fecal or mucosal  A.muciniphila  abundance at the initiation of anti-PD-1 therapy exhibited superior progression-free survival, overall survival, and objective response rates compared  A.muciniphila  -depleted patients, with predictive value exceeding that of tumor PD-L1 expression in some cohorts. Mechanistically, oral supplementation with  A.muciniphila  in germ-free or antibiotic-treated mice colonized with fecal microbiota from non-responder cancer patients restores sensitivity to PD-1 blockade by promoting interleukin-12 (IL-12)-dependent recruitment of CCR9⁺CXCR3⁺CD4⁺ T helper 1 (Th1) lymphocytes and activated dendritic cells into the tumor microenvironment, thereby converting an immunologically “cold” tumor bed into an immunoreactive “hot” milieu. Moreover, transcriptomic profiling of responder tumors enriched in  A.muciniphila reveals upregulation of oxidative phosphorylation, antigen presentation machinery, and interferon-γ signalling pathways, collectively supporting sustained effector T cell function and cytotoxicity [55,56,57,58,59,60,61,62].

In the realm of aging and frailty, A.muciniphila  abundance has been repeatedly associated with longevity phenotypes, healthy aging trajectories, and resilience against age-related multimorbidity. Comparative microbiome surveys show that centenarians and healthy older adults maintain higher A.muciniphila  levels than age-matched individuals with frailty, sarcopenia, or chronic disease, and longitudinal studies suggest that declining A.muciniphila  abundance over time correlates with worsening physical function, immune senescence, and inflammaging—the chronic, low-grade, sterile inflammation that drives age-related pathology. Preclinical interventions in senescent mice reveal that oral A.muciniphila  administration increases mucus layer thickness, restores intestinal barrier integrity, reduces circulating pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), improves immune cell chemotactic activity, enhances natural killer cell function, and mitigates oxidative stress markers in peripheral blood and tissues. Remarkably, A.muciniphila  supplementation in prematurely aged mice and naturally aged mice extends healthspan by improving glucose sensitivity, reducing hepatosplenomegaly, reversing cognitive decline, attenuating muscle atrophy, and upregulating secondary bile acid metabolism, which itself exerts anti-inflammatory and metabolic protective effects. In models of vascular aging, A.muciniphila  alleviates arterial stiffness and vascular calcification induced by vitamin D₃ and nicotine, likely through propionate-mediated modulation of vascular smooth muscle cell phenotype and suppression of inflammatory calcification pathways [2,63,64,65,66].

In neuropsychiatric and neurodegenerative contexts, A.muciniphila  exerts bidirectional effects that appear highly context-dependent. In Alzheimer’s disease (AD) models, oral A.muciniphila  reduces amyloid-β (Aβ) plaque deposition in the brains of APP/PS1 transgenic mice, ameliorates cognitive impairment, reduces anxiety-like behaviours, and normalizes hippocampal synaptic plasticity, effects attributed to restoration of gut barrier function, reduction in systemic inflammation, modulation of peripheral circulating metabolites, and direct influence on microglial activation status. In depression and anxiety models induced by chronic unpredictable mild stress (CUMS) or chronic alcohol exposure,  A.muciniphila  supplementation exerts antidepressant-like effects by increasing serotonin (5-HT) levels in gut tissue, suppressing serotonin transporter (SERT) expression in the intestinal epithelium (thereby increasing local serotonin availability for vagal afferent signalling), and inhibiting activation of enteric nervous system neurons, collectively modulating gut-to-brain signalling via the vagus nerve and reducing depressive-like behaviours. Conversely, in Parkinson’s disease (PD) models and human cohorts, elevated  A.muciniphila  abundance has been associated with accelerated disease progression and increased aggregation of α-synuclein in intestinal enteroendocrine cells, suggesting that in the setting of pre-existing α-synuclein pathology and gut dysmotility, over-colonization by, A.muciniphila  may amplify pathogenic protein misfolding and prion-like spread from the enteric nervous system to the central nervous system. This duality underscores the critical importance of disease context, baseline microbiota composition, and host genetic background in determining whether  A.muciniphila  will exert neuroprotective or potentially deleterious effects [2,67,68,69,70].

Together, these findings across cancer immunotherapy, aging, neurodegeneration, and neuropsychiatry illustrate that A.muciniphila  functions as a systemic immune rheostat and barrier sentinel whose effects radiate beyond the gut to influence immune surveillance in peripheral tumors, chronic inflammatory tone in aging tissues, oxidative resilience in the vasculature and brain, and neuroendocrine signalling along the microbiota-gut-brain axis. Its capacity to modulate inflammaging, enhance anti-tumor immunity, preserve cognitive function, and extend healthspan positions A.muciniphila  as a cornerstone candidate for integrative interventions targeting multi-system resilience in the context of metabolic wellness, cancer care, and aging wellness frameworks [2,5,62,66].

Pasteurized Akkermansia, Outer Membrane Proteins, and Postbiotics

One of the most striking and translationally significant findings in Akkermansia muciniphila research is that heat-inactivated (pasteurized) bacteria and isolated outer membrane components often exert superior metabolic, anti-inflammatory, and barrier-protective effects compared to live cells in both preclinical models and human trials. This counterintuitive observation was first systematically demonstrated by Plovier and colleagues, who reported that pasteurization of A.muciniphila  at 70°C for 30 minutes not only retained but doubled the efficacy of the bacterium in preventing diet-induced obesity, fat mass gain, insulin resistance, and hepatic steatosis in high-fat diet-fed mice. Mechanistic investigations attributed these enhanced effects primarily to a single 34 kDa outer membrane protein designated Amuc_1100, which becomes more bioavailable and stable following heat treatment; when purified and administered alone, recombinant Amuc_1100 replicated the metabolic benefits of pasteurized A.muciniphila , reducing body weight, adiposity, and glucose intolerance at doses as low as 5 μg per day. Amuc_1100 acts via Toll-like receptor 2 (TLR2) on intestinal epithelial cells, triggering downstream AMPK phosphorylation, peroxisome proliferator-activated receptor γ (PPARγ) activation, and enhanced expression of tight junction proteins (occludin, claudin-3, ZO-1), thereby fortifying barrier integrity, reducing lipopolysaccharide translocation, and dampening metabolic endotoxemia [12,71,72,73,74].

Beyond Amuc_1100, additional bioactive components have been isolated and characterized as postbiotic candidates. The P9 protein, an 84 kDa secreted factor encoded by the Amuc_1631 gene, binds to intercellular adhesion molecule-2 (ICAM-2) on enteroendocrine L cells and robustly stimulates glucagon-like peptide-1 (GLP-1) secretion, leading to increased insulin release, reduced food intake, enhanced thermogenesis in brown adipose tissue, and improved glucose tolerance in obese mice. When administered orally or intraperitoneally at 100 μg doses, P9 reduces body weight gain, decreases adipose tissue volume, and upregulates uncoupling protein 1 (UCP1) expression in interscapular brown adipose tissue via an IL-6-dependent pathway, although the physiological relevance of P9 secretion remains debated given its low abundance relative to Amuc_1100 and the absence of consistent GLP-1 changes in human trials with whole pasteurized A.muciniphila . Another secreted enzyme, the β-N-acetylhexosaminidase Amuc_2109, degrades mucin oligosaccharides but also exhibits immunomodulatory properties, reducing NLRP3 inflammasome activation, suppressing pro-inflammatory cytokine release, and preserving goblet cell numbers in dextran sulfate sodium colitis models, positioning it as a dual-function enzyme with both nutritional and signalling roles [5,12,71,72,73,74].

Akkermansia muciniphila-derived extracellular vesicles (AmEVs) represent a third category of postbiotic effectors with distinct advantages in stability, safety, and tissue-targeting capacity. AmEVs are nanoscale (50–200 nm), membrane-bound particles enriched in outer membrane proteins (including Amuc_1100), lipopolysaccharides, peptidoglycans, phosphatidylethanolamine, microRNAs (e.g., let-7i), and enzymatic cargo that can traverse intestinal epithelial barriers and exert effects on distant tissues. In high-fat diet-induced obesity models, oral administration of purified AmEVs reduces body weight gain, improves glucose tolerance, enhances tight junction expression (occludin, claudin-4, ZO-2), and suppresses hepatic steatosis and adipose inflammation more effectively than equivalent doses of live bacteria, without risk of bacterial translocation or infection. AmEVs activate AMPK signalling in intestinal epithelial cells, increase trans-epithelial electrical resistance in lipopolysaccharide-challenged Caco-2 monolayers, and upregulate anti-inflammatory microRNA let-7i in macrophages, thereby suppressing TNF-α and IL-6 secretion and promoting M2 polarization. Importantly, fecal AmEV concentrations are significantly lower in patients with type 2 diabetes compared to healthy controls, and restoration of AmEV levels in diabetic mice correlates with improved metabolic parameters, suggesting that vesicle-mediated signalling is a clinically relevant mode of action [2,5,32,75,76,77].

The superior efficacy and safety profile of pasteurized A.muciniphila  has been validated in human clinical trials. In a landmark randomized, double-blind, placebo-controlled proof-of-concept study, overweight and obese insulin-resistant adults receiving 10¹⁰ colony-forming units of pasteurized A.muciniphila  daily for 3 months exhibited significant improvements in insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp), reductions in plasma total cholesterol, fat mass, hip circumference, and circulating markers of liver dysfunction (aspartate aminotransferase, γ-glutamyltransferase) and inflammation (white blood cell count, plasma lipopolysaccharide-binding protein), whereas live A.muciniphila  showed weaker and non-significant trends. Notably, no serious adverse events or infections were reported, and treatment was well tolerated, addressing critical regulatory concerns about the safety of live next-generation probiotics in metabolically compromised populations. Subsequent studies confirmed that pasteurized A.muciniphila  increases whole-body energy expenditure, spontaneous physical activity, fecal energy excretion, and intestinal epithelial cell turnover while reducing expression of glucose (SGLT1, GLUT2) and fructose (GLUT5) transporters in the jejunum, collectively explaining the observed reductions in body weight and fat mass independent of food intake changes [5,72,78,79].

These converging preclinical and clinical findings establish pasteurized A.muciniphila , Amuc_1100, P9, and AmEVs as a new class of microbiota-derived postbiotics with mechanistic specificity, manufacturing stability, and favourable regulatory pathways compared to live next-generation probiotics. Unlike live bacteria, which face regulatory hurdles related to strain variability, colonization persistence, horizontal gene transfer, and infection risk, defined postbiotic formulations can be standardized by protein content, sterilized by terminal heat treatment, stored at room temperature without viability loss, and dosed with precision based on bioactive molecule concentrations. This translational trajectory positions A.muciniphila – derived postbiotics as scalable, safe, and efficacious therapeutic platforms for metabolic syndrome, obesity, diabetes, inflammatory bowel disease, and potentially aging-related multimorbidity, aligning with regulatory frameworks for biologics and functional foods rather than live microbial drugs [13,80].

Human Clinical Studies and Safety Profile

The first-in-human exploratory trial of Akkermansia muciniphila supplementation provides the strongest current evidence that this next-generation probiotic concept can be translated safely into humans. In a single-center, randomized, double-blind, placebo-controlled study, 40 overweight/obese insulin-resistant adults received daily oral supplementation for 3 months with either live or pasteurized A.muciniphila  (10¹⁰ bacteria/day) or placebo. Pasteurized A.muciniphila  significantly improved peripheral insulin sensitivity by approximately 30% versus placebo (hyperinsulinemic–euglycemic clamp), lowered fasting insulinemia by about 30%, and reduced total plasma cholesterol, while also decreasing markers of liver dysfunction (γ-glutamyltransferase, AST) and low-grade inflammation (white blood cells, lipopolysaccharide-binding protein). Live A.muciniphila showed more modest metabolic benefits, and neither preparation induced serious adverse events, abnormal clinical chemistry, or concerning changes in vital signs, indicating a favourable short‑term safety and tolerability profile in a metabolically vulnerable population [72].

Beyond monostrain supplementation, multi-strain formulations that include A.muciniphila  have been evaluated in type 2 diabetes. In a multicenter, double-blind, randomized trial, a medical probiotic blend (WBF-011) combining A.muciniphila with several butyrate-producing species and the prebiotic inulin, administered for 12 weeks to adults with T2D, significantly reduced total postprandial glucose area-under-the-curve and modestly improved HbA1c compared with placebo, effects accompanied by increased circulating butyrate and bile acid changes consistent with improved metabolic signalling. More recent work in overweight/obese patients with T2D suggests that the glycemic benefit of A.muciniphila supplementation may depend on baseline gut levels of the bacterium, with greater improvements in glucose control observed in individuals with very low initial abundance, underscoring the importance of microbiome stratification for responder prediction. Several ongoing phase 2 trials, such as NCT05114018, which tests pasteurized A.muciniphila  in insulin-resistant but otherwise healthy individuals are designed to refine dose, exposure–response relationships, and safety over longer durations [5,48,79,81,82,83].

From a regulatory standpoint, A.muciniphila and similar “next-generation probiotics” sit at the interface of food, dietary supplement, and drug frameworks, with classification depending on claims, formulation (live vs pasteurized), and intended use. Live A.muciniphila developed as a therapeutic falls under the category of live biotherapeutic products (LBPs) and must comply with investigational new drug (IND) requirements, including detailed chemistry, manufacturing, and control (CMC) data, preclinical safety, and phased clinical evaluation as outlined in FDA and EMA guidance on LBPs. In contrast, pasteurized A.muciniphila and defined components (e.g., Amuc_1100) are increasingly framed as postbiotics and may, in some jurisdictions, be regulated more like novel foods or functional ingredients, provided that health claims remain within nutrition/structure–function boundaries and safety (e.g., absence of viable cells, lack of transferable antibiotic resistance) is demonstrated. As a result, most current human work with A.muciniphila  strategically focuses on pasteurized formulations, which combine stronger metabolic efficacy with a cleaner safety and regulatory profile, positioning them as leading candidates for future metabolic and diabetes-prevention products in the “next-generation probiotic/postbiotic” space [72,84,85,86,87,88,89].

Dietary, Pharmacologic, and Lifestyle Modulators of Akkermansia

Akkermansia muciniphila abundance is highly plastic and can be modulated by diet, drugs, and surgical interventions, creating multiple leverage points for preventive metabolic and aging medicine. Prebiotic fibers such as inulin and oligofructose consistently enrich A.muciniphila  in both rodents and humans; in high-fat diet models, inulin-type fructans increased A.muciniphila  up to fourfold, accompanied by reduced adiposity, improved insulin sensitivity, and attenuation of heaptic statosis and atherosclerosis. A meta-analysis of inulin, galacto-oligosaccharides, and polyphenol interventions in 451 participants confirmed that these substrates significantly increase A.muciniphila abundance, supporting their use as targeting tools for this mucosal symbiont [90,91,92,93].

Dietary polyphenols, particularly cranberry proanthocyanidins, grape polyphenols, and stilbenes, also robustly expand A.muciniphila populations while improving metabolic outcomes. In high-fat-fed mice, grape polyphenol supplementation dramatically increased A.muciniphila, reduced weight gain and adiposity, improved insulin sensitivity, and enhanced intestinal expression of barrier-related genes (occludin, proglucagon), linking A.muciniphila expansion to reduced intestinal and systemic inflammation. Human and translational data suggest that polyphenol-induced A.muciniphila growth involves aryl hydrocarbon receptor (AhR) signalling and IL-22–mediated mucosal repair, further integrating this bacterium into broader immunometabolic networks. Pharmacologically, metformin treatment reproducibly increases A.muciniphila abundance in both animal models and patients with T2D, and this expansion is thought to contribute to its glucose-lowering and weight-stabilizing effects by improving gut barrier function and reducing metabolic endotoxemia [93,94,95,96,97,98,99].

Bariatric surgery, particularly Roux-en-Y gastric bypass, induces one of the most profound and durable shifts in the gut microbiome, with A.muciniphila consistently enriched years after surgery and higher post-operative A.muciniphila levels correlating with greater likelihood of T2D remission. Observational data suggest that individuals who achieve diabetes remission, whether or not the underwent surgery, tends to have higher A.muciniphila abundance than non-remitters, supporting a role for this species as both a mediator and a marker of durable metabolic improvement. Collectively, these findings highlight that diet (prebiotics, polyphenol-rich foods), drugs (metformin), and surgical interventions can be strategically combined to “engineer” a gut environment that fosters A.muciniphila–mediated barrier integrity and metabolic resilience. In an AI-enabled personalization framework, continuous integration of dietary intake, medication use, bariatric status, microbiome sequencing (including A.muciniphila abundance and function), and metabolic phenotypes (CGM profiles, lipidomics, inflammatory markers) could be used to identify individuals with low A.muciniphila or impaired mucosal function and tailor prebiotic, pharmacologic, or surgical strategies to restore this keystone commensal as part of precision preventive care for metabolic and aging wellness [66,96,100,101].

Translational Perspectives for AI Healthtech and Metabolic Wellness

Akkermansia muciniphila is increasingly proposed as a microbiome-derived biomarker and therapeutic target that can be embedded into data-driven, AI-enabled metabolic wellness ecosystems. Its depletion is reproducibly associated with insulin resistance, type 2 diabetes, obesity, cardiovascular risk, and aging-related multimorbidity, whereas higher abundance tracks with better insulin sensitivity, lipid profiles, and gut barrier integrity. These characteristics make A.muciniphila an attractive node for microbiome-informed risk stratification: individuals with very low abundance, impaired mucosal barrier markers, and adverse metabolic phenotypes (e.g., CGM patterns indicating exaggerated postprandial excursions, atherogenic lipidomics profiles) can be algorithmically flagged as candidates for A.muciniphila -supporting interventions such as prebiotic (inulin/oligofructose), polyphenol-rich, or metformin-based strategies, or where appropriate postbiotic supplementation with pasteurized A.muciniphila [9,10,86,94,102,103].

From an AI healthtech perspective, the integration of stool microbiome sequencing (taxonomic and functional features of A.muciniphila and its pathways), continuous glucose monitoring, advanced lipidomics, inflammatory biomarkers, and wearable-derived activity/sleep metrics enables construction of machine learning models that predict metabolic trajectories and responsiveness to A.muciniphila-targeted nutritional or pharmacologic interventions. Multiscale modelling frameworks and multivariate AI algorithms can incorporate A.muciniphila abundance and its co-occurrence networks into host–microbiome interaction maps, helping distinguish when A.muciniphila enrichment is likely to be beneficial (e.g., metabolic syndrome with barrier dysfunction) versus potentially risky (e.g., certain neuroinflammatory or autoimmune contexts), thereby guiding personalized recommendation engines. However, important challenges remain, including assay standardization, temporal variability in microbiome measurements, limited longitudinal intervention data, and the need to translate complex model outputs into simple, actionable protocols for end-users and clinicians. Overcoming these barriers through rigorous validation, interoperable data standards, and careful clinical integration could allow A.muciniphila –centric metrics to become part of scalable, preventive programs that couple precision nutrition, smart supplementation, and digital coaching to maintain metabolic and aging wellness across the life course [66,84,104,105,106,107,108,109].

Limitations, Risks, and Open Questions

Despite compelling preclinical and early clinical data, substantial limitations, risks, and open questions remain before Akkermansia muciniphila can be widely deployed as a therapeutic tool. First, there is marked strain-level and phylogroup variability in mucin-degrading capacity, oxygen tolerance, immunostimulatory profiles, and antibiotic resistance patterns, meaning that results obtained with the reference MucT strain or specific engineered strains (e.g., Akk11) may not generalize to naturally occurring or commercial isolates, and rigorous strain-specific genomic and phenotypic safety characterization is essential. Second, optimal dose, duration, and formulation (live vs pasteurized cells vs defined postbiotics) remain incompletely defined, and context-dependent effects have been documented: in fiber-deprived mice and certain dysbiotic states, A.muciniphila expansion exacerbates food allergy, Salmonella-induced colitis, or central nervous system autoimmunity by over-consuming mucus, altering Clostridia/SCFA networks, and amplifying Th2/Th17 responses, underscoring that benefits are not universal and may depend critically on diet and microbiome ecology. Third, human data are still limited to small, short-term trials; while pasteurized A.muciniphila and specific postbiotics have shown good tolerability and no acute adverse signals, long-term safety, especially regarding mucosal barrier integrity, colorectal cancer risk, and neurological outcomes has not been established, and only recently have regulatory bodies such as EFSA begun issuing positive safety opinions for pasteurized preparations as novel foods. Methodologically, most evidence linking A.muciniphila to disease states arises from cross-sectional 16S or metagenomic studies that are vulnerable to confounding, reverse causality, batch effects, and analytical heterogeneity, complicating causal inference and cross-study comparisons. Future interventional research will require standardized microbiome assays (species- and strain-resolved quantification), harmonized clinical endpoints (e.g., insulin sensitivity by clamp, validated IBD activity indices, hard cardiovascular outcomes), and adequately powered, multi-ethnic, long-duration randomized trials to definitively establish when, for whom, and in what form A.muciniphila –based interventions confer net benefit versus potential harm [110,111,112].

Akkermansia as a Cornerstone for Next-Generation Metabolic and Aging Therapies

Akkermansia muciniphila and its derived postbiotics now stand at the forefront of next‑generation probiotic strategies, uniquely positioned at the intersection of barrier biology, immune calibration, and metabolic regulation across the lifespan. By reinforcing mucosal integrity, reducing metabolic endotoxemia, promoting regulatory immune networks, and enhancing metabolic flexibility in preclinical models and early human trials, A.muciniphila exemplifies how a single mucin-adapted commensal can function as both biomarker and effector in cardiometabolic, neuroimmune, and aging-related health. The emergence of pasteurized A.muciniphila, outer membrane proteins such as Amuc_1100, secreted proteins like P9, and extracellular vesicles as potent, stable postbiotic modalities further strengthens its translational potential by enabling standardized, safe, and mechanistically targeted formulations that overcome many limitations of live biotherapeutics. Moving from promise to practice will require rigorous mechanistic studies, long-term randomized controlled trials with harmonized endpoints, and careful attention to context-specific risks, but also deliberate integration with AI-driven personalization frameworks that combine microbiome, CGM, lipidomics, and clinical phenotyping to identify who benefits, when, and from which A.muciniphila –centered interventions. If these scientific, clinical, and digital challenges can be met, A.muciniphila is poised to transition from a “shining star” of gut ecology to a validated therapeutic pillar in precision metabolic and aging wellness medicine.

Reference

  1. Ouwerkerk JP, van der Ark KCH, Davids M, Claassens NJ, Finestra TR, de Vos WM, et al. Adaptation of Akkermansia muciniphila to the Oxic-Anoxic Interface of the Mucus Layer. Applied and Environmental Microbiology [Internet]. 2016 Nov 9;82(23):6983–93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103097/#:~:text=capacities were studied.-
  2. Zeng SY, Liu YF, Liu JH, Zeng ZL, Xie H, Liu JH. Potential Effects of Akkermansia Muciniphilain Aging and Aging-Related Diseases: Current Evidence and Perspectives. Aging and disease [Internet]. 2023 Jan 1;14(6):2015–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676789/#:~:text=muciniphila may exert beneficial regulatory
  3. Guo X, Zhang J, Wu F, Zhang M, Yi M, Peng Y. Different subtype strains of Akkermansia muciniphilaabundantly colonize in southern China. Journal of Applied Microbiology. 2015 Dec 15;120(2):452–9.
  4. Kostopoulos I, Elzinga J, Ottman N, Klievink JT, Blijenberg B, Aalvink S, et al. Akkermansia muciniphila uses human milk oligosaccharides to thrive in the early life conditions in vitro. Scientific Reports. 2020 Aug 31;10(1).
  5. Rodrigues VF, Elias-Oliveira J, Pereira ÍS, Pereira JA, Barbosa SC, Machado MSG, et al. Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes. Frontiers in Immunology [Internet]. 2022 Jul 7;13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300896/pdf/fimmu-13-934695.pdf
  6. Mo C, Lou X, Xue J, Shi Z, Zhao Y, Wang F, et al. The influence of Akkermansia muciniphila on intestinal barrier function. Gut Pathogens. 2024 Aug 3;16(1).
  7. Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J, et al. Microbial Metabolic Networks at the Mucus Layer Lead to Diet-Independent Butyrate and Vitamin B12 Production by Intestinal Symbionts. Dubilier N, editor. mBio. 2017 Sep 19;8(5).
  8. Pichler MJ, Yamada C, Shuoker B, Alvarez-Silva C, Gotoh A, Leth ML, et al. Butyrate producing colonic Clostridiales metabolise human milk oligosaccharides and cross feed on mucin via conserved pathways. Nature Communications. 2020 Jul 3;11(1).
  9. Yan J, Sheng L, Li H. Akkermansia muciniphila: is it the Holy Grail for ameliorating metabolic diseases? Gut Microbes. 2021 Jan 1;13(1).
  10. Shaheen N, Khursheed W, Gurung B, Wang S. Akkermansia muciniphila: A key player in gut microbiota-based disease modulation. Microbiological Research. 2025 Dec;301:128317.
  11. Xue C, Li G, Gu X, Su Y, Zheng Q, Yuan X, et al. Health and Disease: Akkermansia muciniphila, the Shining Star of the Gut Flora. Research [Internet]. 2023 Jan 1;6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079265/
  12. Wade H, Pan K, Duan Q, Kaluzny S, Pandey E, Fatumoju L, et al. Akkermansia muciniphila and its membrane protein ameliorates intestinal inflammatory stress and promotes epithelial wound healing via CREBH and miR-143/145. Journal of Biomedical Science. 2023 Jun 7;30(1).
  13. Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Experimental & Molecular Medicine. 2018 Feb;50(2):e450–0.
  14. Zheng M, Han R, Yuan Y, Xing Y, Zhang W, Sun Z, et al. The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives. Frontiers in Immunology [Internet]. 2022;13:1089600. Available from: https://pubmed.ncbi.nlm.nih.gov/36685588/
  15. Qian K, Chen S, Wang J, Sheng K, Wang Y, Zhang M. A β-N-acetylhexosaminidase Amuc_2109 from Akkermansia muciniphila Protects against Dextran Sulfate Sodium-induced Colitis in Mice by Enhancing Intestinal Barrier and Modulating Gut Microbiota. Food & Function. 2022;
  16. Jiang P, Ji S, Su D, Zhao Y, Goncalves VBE, Xu G, et al. The biofunction of Akkermansia muciniphilain intestinal-related diseases. Microbiome Research Reports. 2024 Sep 5;3(4).
  17. Molaaghaee-Rouzbahani S, Nastaran Asri, Sapone A, Kaveh Baghaei, Yadegar A, Amani D, et al. Akkermansia muciniphila exerts immunomodulatory and anti-inflammatory effects on gliadin-stimulated THP-1 derived macrophages. Scientific Reports. 2023 Feb 24;13(1).
  18. Qu S, Fan L, Qi Y, Xu C, Hu Y, Chen S, et al. Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation. Claesen J, editor. Microbiology Spectrum. 2021 Oct 31;9(2).
  19. Si J, Kang H, You HJ, Ko G. Revisiting the role of Akkermansia muciniphilaas a therapeutic bacterium. Gut Microbes. 2022 May 25;14(1).
  20. Zhang H, Pan Y, Jiang Y, Chen M, Ma X, Yu X, et al. Akkermansia muciniphila ONE effectively ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. npj Science of Food. 2024 Nov 19;8(1).
  21. Luo ZW, Xia K, Liu YW, Liu JH, Rao SS, Hu XK, et al. Extracellular Vesicles from Akkermansia muciniphila Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages. International Journal of Nanomedicine. 2021 Apr;Volume 16:2949–63.
  22. Filippo Liviero, Pavanello S. Epidemiological and mechanistic links between PM2.5 exposure and type 2 diabetes: focus on the TRPV1 receptor. Frontiers in Endocrinology. 2025 Sep 2;16.
  23. Chiantera V, Laganà AS, Basciani S, Nordio M, Bizzarri M. A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms. Life [Internet]. 2023 Jun 1;13(6):1247. Available from: https://www.mdpi.com/2075-1729/13/6/1247
  24. Panzetta ME, Valdivia RH. Akkermansiain the gastrointestinal tract as a modifier of human health. Gut Microbes. 2024 Sep 21;16(1).
  25. Suwandi A, Ocvirk S, Galeev A, Basic M, Naderi RRA, Tientcheu Tchokoafi DD, et al. Akkermansia muciniphila ameliorates Salmonella-induced colitis and intestinal fibrosis. Mucosal immunology [Internet]. 2025 Dec;18(6):1381–93. Available from: https://pubmed.ncbi.nlm.nih.gov/40962179/
  26. Wu W, Kaicen W, Bian X, Yang L, Ding S, Li Y, et al. Akkermansia muciniphila alleviates high‐fat‐diet‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids. Microbial Biotechnology [Internet]. 2023 Jun 28 [cited 2024 Jan 8];16(10):1924–39. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527187/
  27. Chen H, Cao T, Lin C, Jiao S, He Y, Zhu Z, et al. Akkermansia muciniphila ameliorates olanzapine-induced metabolic dysfunction-associated steatotic liver disease via PGRMC1/SIRT1/FOXO1 signaling pathway. Frontiers in Pharmacology. 2025 Mar 19;16:1550015–5.
  28. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Frontiers in Microbiology. 2020 Feb 21;11(219).
  29. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Scientific Reports. 2015 Nov 13;5(1).
  30. Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes [Internet]. 2021 Jan 1;13(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158032/
  31. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences. 2013 May 13;110(22):9066–71.
  32. Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim J, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology. 2021 Apr 5;6(5):563–73.
  33. Yang L, Huang Y, Chen M, Ma X, Yu X, Ren D, et al. Pasteurized Akkermansia muciniphila AKK PROBIO Attenuates Obesity Through Gut Microbiota-SCFA-GLP-1 Axis and Potential Involvement of AMPK/PPAR-α Pathway. Probiotics and Antimicrobial Proteins. 2025 Oct 22;
  34. Hu Y, Zhou J, Lin X. Akkermansia muciniphila helps in the recovery of lipopolysaccharide-fed mice with mild intestinal dysfunction. Frontiers in Microbiology. 2025 Mar 12;16.
  35. Sankarganesh P, Bhunia A, Ganesh Kumar A, Babu S, Gopukumar ST, Lokesh E. Short-Chain Fatty Acids (SCFAs) in Gut Health: Implications for Drug Metabolism and Therapeutics. Medicine in Microecology [Internet]. 2025 Jul 10;100139. Available from: https://www.sciencedirect.com/science/article/pii/S2590097825000205
  36. Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim J, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology. 2021 Apr 5;6(5):563–73.
  37. Zhuge A, Li S, Han S, Yuan Y, Shen J, Wu W, et al. Akkermansia muciniphila-derived acetate activates the hepatic AMPK/SIRT1/PGC-1α axis to alleviate ferroptosis in metabolic-associated fatty liver disease. Acta Pharmaceutica Sinica B [Internet]. 2024 Oct 28; Available from: https://www.sciencedirect.com/science/article/pii/S2211383524004106
  38. Dianti I, I Putu Hendri Aryadi, Made I. Review of Literature on Akkermansia muciniphila and its Possible Role in the Etiopathogenesis and Therapy of Type 2 Diabetes Mellitus. 2022 May 26;37(1):69–74. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242659/#:~:text=Figure 1-
  39. Han Y, Ling Q, Wu L, Wang X, Wang Z, Chen J, et al. Akkermansia muciniphilainhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization. Gut microbes. 2023 Jun 22;15(1).
  40. Liu C, Ma R, Li H, Pan X, Qian H, Yang T, et al. Akkermansia muciniphila ameliorates fatty liver through microbiota-derived α-ketoisovaleric acid metabolism and hepatic PI3K/Akt signaling. iScience [Internet]. 2025 Apr 16;28(5):112458. Available from: https://www.sciencedirect.com/science/article/pii/S2589004225007199
  41. Ghaderi F, Sotoodehnejadnematalahi F, Hajebrahimi Z, Fateh A, Siadat SD. Effects of active, inactive, and derivatives of Akkermansia muciniphila on the expression of the endocannabinoid system and PPARs genes. Scientific Reports. 2022 Jun 15;12(1).
  42. Srivastava RK, Lutz B, Ruiz de Azua I. The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism. Frontiers in Cellular Neuroscience [Internet]. 2022 May 11;16:867267. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130962/
  43. Jansma J, Brinkman F, van Hemert S, El Aidy S. Targeting the endocannabinoid system with microbial interventions to improve gut integrity. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021 Mar;106:110169.
  44. Shih CT, Yeh YT, Lin CC, Yang LY, Chiang CP. Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. Microorganisms. 2020 Sep 5;8(9):1360.
  45. Crudele L, Raffaella Maria Gadaleta, Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine. 2023 Nov 1;97:104821–1.
  46. Zhang Q, Hu N. Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020 Dec;Volume 13:5003–14.
  47. Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Frontiers in endocrinology [Internet]. 2025;15:1486793. Available from: https://pubmed.ncbi.nlm.nih.gov/39897957/
  48. Li J, Yang G, Zhang Q, Liu Z, Jiang X, Xin Y. Function of Akkermansia muciniphila in type 2 diabetes and related diseases. Frontiers in Microbiology. 2023 Jun 15;14.
  49. Saiedi E, Reza Shapouri, Fakhri Haghi, Habib Zeighami. Comparative analysis of gut microbiota composition in the fecal samples from type 2 diabetes mellitus patients and healthy individuals: a case control study. Iranian Journal of Microbiology. 2025 Dec 10;
  50. Zhang L, Chu J, Hao W, Zhang J, Li H, Yang C, et al. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications. Mediators of Inflammation [Internet]. 2021 Aug 17;2021:e5110276. Available from: https://www.hindawi.com/journals/mi/2021/5110276/
  51. Zhang C, Wang Z, Liu X, Liu X, Liu T, Feng Y, et al. Akkermansia muciniphilaadministration ameliorates streptozotocin‐induced hyperglycemia and muscle atrophy by promoting IGF2 secretion from mouse intestine. iMeta. 2024 Oct 1;3(5):e237–7.
  52. Maddux S, Lubin JB, Green J, Flores J, Rozich I, Tereza Duranova, et al. Modulation of adaptive immune responses by Akkermansia muciniphilais restricted to an early life window in NOD mice. bioRxiv (Cold Spring Harbor Laboratory). 2022 Aug 17;
  53. Huang Baojiang, Chen Qiuli. Akkermansia muciniphila induces immune homeostasis in type 1 diabetic mice by up-regulating CD4 + FoxP3 + Treg expression. ESPE Abstracts [Internet]. 2024 Oct 28 [cited 2026 Jan 5];98. Available from: https://abstracts.eurospe.org/hrp/0098/hrp0098rfc1.3
  54. Rampanelli E, Nieuwdorp M. Gut microbiome in type 1 diabetes: the immunological perspective. Expert Review of Clinical Immunology. 2022 Nov 28;19(1):93–109.
  55. Li L, McAllister F. Too much water drowned the miller: Akkermansia determines immunotherapy responses. Cell Reports Medicine. 2022 May 1;3(5):100642–2.
  56. Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2019 Jul 23;7(1).
  57. Shimizu T, Ryotaro Ohkuma, Homma M, Nakayama S, Sasaki Y, Muto S, et al. Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Frontiers in Immunology. 2025 Sep 8;16:1528594–4.
  58. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2017 Nov 2;359(6371):97–103.
  59. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine. 2022 Feb;28(2):315–24.
  60. Fan P, Ni M, Fan Y, Ksiezarek M, Fang G. Predictive power of different Akkermansiaphylogroups in clinical response to PD-1 blockade against non-small cell lung cancer. 2024 Aug 22 [cited 2026 Jan 5]; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11370331/
  61. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, NY). 2018;359(6371):91–7.
  62. Shi Y, Fu Y, Tang D. The microbial revolution: Akkermansia muciniphila’s role in overcoming immunotherapy challenges. International immunopharmacology [Internet]. 2025;164:115374. Available from: https://pubmed.ncbi.nlm.nih.gov/40834528/
  63. Haran JP, McCormick BA. Aging, Frailty, and the Microbiome—How Dysbiosis Influences Human Aging and Disease. Gastroenterology. 2021 Jan;160(2):507–23.
  64. Mu J, Lin Q, Wang S, Chen M, Wang J, Chen Y, et al. TNF-α modulation by rice bran peptides: implications for gut microbiota stability and cognitive health in aging. npj Biofilms and Microbiomes [Internet]. 2025 Oct 9 [cited 2026 Jan 5];11(1). Available from: https://www.nature.com/articles/s41522-025-00830-7
  65. Xiao Y, Feng Y, Zhao J, Chen W, Lu W. Achieving healthy aging through gut microbiota-directed dietary intervention: Focusing on microbial biomarkers and host mechanisms. Journal of Advanced Research. 2024 Mar 1;
  66. Gyriki D, Nikolaidis CG, Bezirtzoglou E, Voidarou C, Stavropoulou E, Tsigalou C. The gut microbiota and aging: interactions, implications, and interventions. Frontiers in Aging [Internet]. 2025 May 14;6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12116569/
  67. Lei W, Cheng Y, Gao J, Liu X, Shao L, Kong Q, et al. Akkermansia muciniphila in neuropsychiatric disorders: friend or foe? Frontiers in Cellular and Infection Microbiology. 2023 Jul 10;13.
  68. Khalili L, Park G, Nagpal R, Bhide P, Salazar G. The Impact of Akkermansia muciniphila on Mouse Models of Depression, Anxiety, and Stress: A Systematic Review and Meta-Analysis. Current Neuropharmacology. 2025 Mar 18;23.
  69. Maftoon H, Davar Siadat S, Tarashi S, Soroush E, Basir Asefi M, Rahimi Foroushani A, et al. Ameliorative effects of Akkermansia muciniphila on anxiety-like behavior and cognitive deficits in a rat model of Alzheimer’s disease. Brain research [Internet]. 2024 Autumn;1845:149280. Available from: https://pubmed.ncbi.nlm.nih.gov/39419309/
  70. Guo H, Liu X, Chen T, Wang X, Zhang X. Akkermansia muciniphila Improves Depressive-Like Symptoms by Modulating the Level of 5-HT Neurotransmitters in the Gut and Brain of Mice. Molecular neurobiology. 2023 Sep 5;61(2):821–34.
  71. Campbell K. New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial [Internet]. Gut Microbiota for Health. 2016 [cited 2026 Jan 5]. Available from: https://www.gutmicrobiotaforhealth.com/new-insights-akkermansia-muciniphila-improves-metabolic-health-leading-first-human-safety-trial/
  72. Depommier C, Van Hul M, Everard A, Delzenne NM, De Vos WM, Cani PD. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes. 2020 Mar 13;11(5):1231–45.
  73. Sulaiman JE, Zhan Y, Wang S, Lai KL, Li JHW, Yutong DY, et al. Proteomic study of Akkermansia muciniphila and Bifidobacterium species co-culture under different carbon sources. Frontiers in Microbiology. 2025 Nov 6;16.
  74. Zheng X, Huang W, Li Q, Chen Y, Wu L, Dong Y, et al. Membrane Protein Amuc_1100 Derived from Akkermansia muciniphila Facilitates Lipolysis and Browning viaActivating the AC3/PKA/HSL Pathway. Microbiology spectrum. 2023 Apr 13;11(2).
  75. Segers A, de Vos WM. Mode of action of Akkermansia muciniphila in the intestinal dialogue: role of extracellular proteins, metabolites and cell envelope components. Microbiome Research Reports. 2023;2(2):6.
  76. Qian K, Chen S, Wang J, Sheng K, Wang Y, Zhang M. A β-N-acetylhexosaminidase Amuc_2109 from Akkermansia muciniphila Protects against Dextran Sulfate Sodium-induced Colitis in Mice by Enhancing Intestinal Barrier and Modulating Gut Microbiota. Food & Function. 2022;
  77. He Z, Song W, Zhang S, Zhao M, Wang F, He S, et al. The efficacy of Akkermansia muciniphila YGMCC2602-derived postbiotics in skin repair. Journal of Functional Foods. 2025 Jul 2;131:106950–0.
  78. Abot A, Amandine Brochot, Pomié N, Gwendoline Astre, Céline Druart, Willem, et al. Pasteurized Akkermansia muciniphila improves glucose metabolism is linked with increased hypothalamic nitric oxide release. Heliyon. 2023 Jul 1;9(7):e18196–6.
  79. gov. 2026 [cited 2026 Jan 5]. Available from: https://www.clinicaltrials.gov/study/NCT05114018
  80. Wang Y, Lin W, Wu S, He X, Ou Z, Zheng L. Akkermansia muciniphila extracellular vesicles: Function and theranostic potential in disease. LabMed Discovery. 2025 Mar;2(1):100060.
  81. Zhang Y, Liu R, Chen Y, Cao Z, Liu C, Bao R, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metabolism [Internet]. 2025 Jan 1; Available from: https://www.cell.com/cell-metabolism/abstract/S1550-4131(24)00492-3
  82. Liu E, Ji X, Zhou K. Akkermansia muciniphila for the Prevention of Type 2 Diabetes and Obesity: A Meta-Analysis of Animal Studies. Nutrients. 2024 Oct 11;16(20):3440–0.
  83. Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Research & Care. 2020 Jul;8(1):e001319.
  84. Barberio D. Navigating regulatory and analytical challenges in live biotherapeutic product development and manufacturing. Frontiers in Microbiomes. 2024 Aug 15;3.
  85. Dreher-Lesnick SM, Stibitz S, Carlson, Jr. PE. U.S. Regulatory Considerations for Development of Live Biotherapeutic Products as Drugs. Microbiology Spectrum. 2017 Oct 3;5(5).
  86. Niu H, Zhou M, Zogona D, Xing Z, Wu T, Chen R, et al. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases. Frontiers in Immunology [Internet]. 2024 Mar 20;15:1370658. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10987721/
  87. Jan T, Negi R, Sharma B, Kumar S, Singh S, Ashutosh Kumar Rai, et al. Next generation probiotics for human health: An emerging perspective. Heliyon. 2024 Aug 1;10(16):e35980–0.
  88. Research C for BE and. Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry [Internet]. U.S. Food and Drug Administration. 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information
  89. Zhang T, Li Q, Cheng L, Buch H, Zhang F. Akkermansia muciniphila is a promising probiotic. Microbial Biotechnology. 2019 Apr 21;12(6):1109–25.
  90. Pérez-Monter C, Álvarez-Arce A, Nuño-Lambarri N, Escalona-Nández I, Juárez-Hernández E, Chávez-Tapia NC, et al. Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. International Journal of Molecular Sciences. 2022 Jan 17;23(2):991.
  91. Tian R, Yu L, Tian F, Zhao J, Chen W, Zhai Q. Effect of inulin, galacto-oligosaccharides, and polyphenols on the gut microbiota, with a focus on Akkermansia muciniphila. Food & Function [Internet]. 2024 [cited 2025 Aug 15];15(9):4763–72. Available from: https://pubs.rsc.org/en/content/articlelanding/2024/fo/d4fo00428k
  92. Zhu L, Qin S, Zhai S, Gao Y, Li L. Inulin with different degrees of polymerization modulates composition of intestinal microbiota in mice. FEMS Microbiology Letters. 2017 Apr 12;364(10).
  93. com. 2016. Available from: https://gut.bmj.com/content/67/2/271
  94. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, et al. Dietary Polyphenols Promote Growth of the Gut BacteriumAkkermansia muciniphilaand Attenuate High-Fat Diet–Induced Metabolic Syndrome. Diabetes. 2015 Apr 6;64(8):2847–58.
  95. Van CB, Seitz VA, Metcalf JL, Raskin I. Dietary Polyphenols Support Akkermansia muciniphila Growth via Mediation of the Gastrointestinal Redox Environment. Antioxidants. 2024 Feb 29;13(3):304–4.
  96. Mabey JG, Chaston JM, Castro DG, Adams TD, Hunt SC, Davidson LE. Gut microbiota differs a decade after bariatric surgery relative to a nonsurgical comparison group. Surgery for Obesity and Related Diseases. 2020 Sep;16(9):1304–11.
  97. Rodríguez-Daza MC, de Vos WM. Polyphenols as Drivers of a Homeostatic Gut Microecology and Immuno-Metabolic Traits of Akkermansia muciniphila: From Mouse to Man. International Journal of Molecular Sciences. 2022 Dec 20;24(1):45.
  98. Zhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. Journal of functional foods [Internet]. 2017 Jun 1;33:194–201. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223323/
  99. Anonye BO. Commentary: Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome. Frontiers in Immunology. 2017 Jul 27;8.
  100. Yan M, Song MM, Bai RX, Cheng S, Yan WM. Effect of Roux-en-Y gastric bypass surgery on intestinalAkkermansia muciniphila. World Journal of Gastrointestinal Surgery. 2016;8(4):301.
  101. Zhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. Journal of functional foods [Internet]. 2017 Jun 1;33:194–201. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223323/
  102. com. 2016. Available from: https://gut.bmj.com/content/67/2/271
  103. Zeng Z, Chen M, Liu Y, Zhou Y, Liu H, Wang S, et al. Role of Akkermansia muciniphilain insulin resistance. Journal of Gastroenterology and Hepatology. 2024 Oct 13;
  104. Xue C, Li G, Gu X, Su Y, Zheng Q, Yuan X, et al. Health and Disease: Akkermansia muciniphila, the Shining Star of the Gut Flora. Research [Internet]. 2023 Jan 1;6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079265/
  105. Martínez-González MA, Planes FJ, Ruiz-Canela M, Toledo E, Ramón Estruch, Jordi Salas-Salvadó, et al. Recent advances in precision nutrition and cardiometabolic diseases. Revista Española de Cardiología (English Edition). 2024 Sep 1;
  106. Javad Aminian-Dehkordi, Dickson A, Amin Valiei, Mohammad. MetaBiome: a multiscale model integrating agent-based and metabolic networks to reveal spatial regulation in gut mucosal microbial communities. mSystems. 2025 Apr 4;10(5):e0165224–4.
  107. Alexandrescu L, Tofolean IT, Condur LM, Tofolean DE, Nicoara AD, Serbanescu L, et al. Smart Microbiomes: How AI Is Revolutionizing Personalized Medicine. Bioengineering [Internet]. 2025 Aug 31 [cited 2025 Nov 23];12(9):944. Available from: https://www.mdpi.com/2306-5354/12/9/944
  108. Zhou T, Zhao F. AI-empowered human microbiome research. Gut [Internet]. 2025 Sep 22;gutjnl-2025. Available from: https://gut.bmj.com/content/early/2025/09/22/gutjnl-2025-335946
  109. Levy R, Borenstein E. Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules. Proceedings of the National Academy of Sciences. 2013 Jul 15;110(31):12804–9.
  110. Ye WY, Cai Y. Akkermansia muciniphila: a microbial guardian against oxidative stress–gut microbiota crosstalk and clinical prospects. Journal of Translational Medicine [Internet]. 2025 Oct 24;23(1):1169–9. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12551360/
  111. Luo Y, Lan C, Li H, Ouyang Q, Kong F, Wu A, et al. Rational consideration of Akkermansia muciniphila targeting intestinal health: advantages and challenges. npj Biofilms and Microbiomes. 2022 Oct 17;8(1).
  112. Peipert D, Montgomery TL, Toppen LC, Frances M, Scarborough MJ, Krementsov DN. Colonization by Akkermansia muciniphila modulates central nervous system autoimmunity in an ecological context-dependent manner. Frontiers in Immunology. 2025 Oct 13;16:1655428–8.

‌